190 related articles for article (PubMed ID: 23879199)
1. Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea.
Verner E; Forsyth C; Grigg A
Leuk Lymphoma; 2014 May; 55(5):1139-43. PubMed ID: 23879199
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
3. Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children.
Knöfler R; Lange BS; Paul F; Tiebel O; Suttorp M
Br J Haematol; 2020 Mar; 188(5):701-706. PubMed ID: 31617211
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
Appelmann I; Kreher S; Parmentier S; Wolf HH; Bisping G; Kirschner M; Bergmann F; Schilling K; Brümmendorf TH; Petrides PE; Tiede A; Matzdorff A; Griesshammer M; Riess H; Koschmieder S
Ann Hematol; 2016 Apr; 95(5):707-18. PubMed ID: 26916570
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
[TBL] [Abstract][Full Text] [Related]
6. Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders.
Baron BW; Mick R; Baron JM
Cancer; 1993 Aug; 72(4):1209-18. PubMed ID: 8339212
[TBL] [Abstract][Full Text] [Related]
7. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Kander EM; Raza S; Zhou Z; Gao J; Zakarija A; McMahon BJ; Stein BL
Int J Hematol; 2015 Nov; 102(5):587-93. PubMed ID: 26440973
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic and bleeding complications in classical myeloproliferative neoplasms.
McMahon B; Stein BL
Semin Thromb Hemost; 2013 Feb; 39(1):101-11. PubMed ID: 23264112
[TBL] [Abstract][Full Text] [Related]
9. Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis.
Trotti C; Sant'Antonio E; Vanni D; Casetti IC; Borsani O; Pietra D; Ferretti VV; Astori C; Arcaini L; Rumi E
Hematol Oncol; 2021 Oct; 39(4):589-592. PubMed ID: 34320245
[No Abstract] [Full Text] [Related]
10. Second malignancies in philadelphia-negative myeloproliferative neoplasms-single-center experience.
Kissova J; Ovesna P; Penka M; Bulikova A; Kiss I
Anticancer Res; 2014 May; 34(5):2489-96. PubMed ID: 24778065
[TBL] [Abstract][Full Text] [Related]
11. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.
van Genderen PJ; Michiels JJ; van der Poel-van de Luytgaarde SC; van Vliet HH
Ann Hematol; 1994 Aug; 69(2):81-4. PubMed ID: 8080884
[TBL] [Abstract][Full Text] [Related]
12. Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib.
Breccia M; Cannella L; Diverio D; Streponi P; Nanni M; Stefanizzi C; Natalino F; Mecarocci S; Alimena G
Leuk Res; 2008 Jan; 32(1):177-80. PubMed ID: 17688946
[TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
14. Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome.
Kogan L; Price R; Kotchetkov R
Front Oncol; 2024; 14():1326209. PubMed ID: 38361779
[TBL] [Abstract][Full Text] [Related]
15. Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.
Gianelli U; Iurlo A; Cattaneo D; Lambertenghi-Deliliers G
Expert Rev Hematol; 2014 Apr; 7(2):255-64. PubMed ID: 24524231
[TBL] [Abstract][Full Text] [Related]
16. Chip-based digital polymerase chain reaction technology is useful for monitoring the JAK2 V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.
Furuya D; Moriai M; Murai R; Moriai R; Koizumi Y; Endo T; Asanuma K; Yanagihara N; Takahashi S
Int J Lab Hematol; 2019 Oct; 41(5):e113-e116. PubMed ID: 30903743
[No Abstract] [Full Text] [Related]
17. Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
Caramazza D; Caracciolo C; Barone R; Malato A; Saccullo G; Cigna V; Berretta S; Schinocca L; Quintini G; Abbadessa V; Di Raimondo F; Siragusa S
Ann Hematol; 2009 Oct; 88(10):967-71. PubMed ID: 19214510
[TBL] [Abstract][Full Text] [Related]
18. Triple-Negative Essential Thrombocythemia Complicated by Thrombosis and Acquired von Willebrand Disease in a Young Man.
Kanderi T; Puthenpura M; Shrimanker I; Sapna F; Felter SC
Am J Case Rep; 2020 Aug; 21():e924560. PubMed ID: 32829377
[TBL] [Abstract][Full Text] [Related]
19. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
Mihaila RG
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Mar; 161(1):50-53. PubMed ID: 28145534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
